Promimic AB
The answer first
Does Promimic beat the market?
No, Promimic has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 27% of Nordic stocks
- Quality80
- Value19
- Trend21
No. 111 of 195 in healthcare
Max for seven days
Follow Promimic with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Promimic
Your first answer is free, no account needed.
Do you own Promimic, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Promimic and a few more. Free, no card.
Super Stock+45.9%In short
- Promimic has fallen 31.3% over the past year, including dividends.
- Overall, Promimic ranks better than 27% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 80.9%. The price is 79.4% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 27% of Nordic stocks.
No. 111 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 54 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.02
- Asset turnoverSales divided by everything the company owns0.66
- Return on equityProfit divided by equity−14.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 101 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity2.8
- P/SPrice divided by sales3.3
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 120 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−7.2%
- 6 months−25.4%
- 9 months−30.4%
- 12 months−31.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Promimic
One fund we follow owns Promimic. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Promimic
Promimic AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 17 employees.
Promimic AB (publ) engages in the manufacturing, marketing, and sale of biomaterials for improved osseointegration in the orthopedic and dental implants markets in Sweden. It offers HAnano surface which combines several properties that are known to improve osseointegration into one unique surface modification; and nano-sized crystalline powder or suspension hydroxyapatite can be used in r and d, as an ingredient in bone substitutes or as a chromatography material. The company was incorporated in 2004 and is headquartered in Mölndal, Sweden.


See the full analysis of Promimic.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card